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Fibrosis mediated by transforming growth factor-b (TGF-b) is
a common cause of peritoneal dialysis (PD) failure. In a model
of peritoneal fibrosis, we tested the effect of Smad7, an
inhibitor of TGF-b signaling, using an ultrasound-
microbubble-mediated delivery system. Rats were given daily
PD for 4 weeks and received Smad7 or control plasmid
transfer. The ultrasound technique enhanced Smad7
expression in a dose-dependent manner in more than 80% of
the peritoneal cells after 3 days. The expression decreased by
14 days, but this was corrected by a second gene transfer.
The overexpression of Smad7 substantially inhibited Smad2/
3 activation, TGF-b, plasminogen activator inhibitor-1,
extracellular matrix, and myofibroblast mRNA, and protein
expression in the peritoneal cells. The decreased peritoneal
injury included the rise of mass transfer of glucose, a
reduction of the ultrafiltration rate, and fibrotic thickening.
Our studies suggest that ultrasound-mediated Smad7 gene
delivery may be useful in the prevention or treatment of
dialysis-induced peritoneal fibrosis.
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Patients with end-stage renal disease requiring dialysis have
been increased markedly over the last decades, and this
phenomenon continues to grow steadily. Among dialysis
therapies, peritoneal dialysis (PD) is a convenient and
inexpensive therapy over hemodialysis. However, these
advantages are lost in long-term PD, mainly due to the
fibrotic changes in the peritoneal membrane caused by the
use of conventional bio-incompatible PD solutions.
Increasing evidence shows that transforming growth
factor-b (TGF-b) is a key mediator in dialysis-related
peritoneal fibrosis.1 Indeed, the levels of TGF-b increase in
dialysis effluents in patients with PD and the high levels of
TGF-b predict peritoneal fibrosis.1–4 It is now clear that TGF-
b is produced by peritoneal macrophages in patients with
PD2 and by mesothelial cells under high dialysate glucose
concentration.4,5 Upregulation of peritoneal TGF-b levels is
associated with production of extracellular matrix (ECM)
molecules such as collagens and fibronectin.4 The functional
importance of TGF-b in peritoneal fibrosis is further
demonstrated by the finding that overexpression of TGF-b
by gene transfer of rat peritoneum leads to fibrosis with loss
of ultrafiltration.6,7 In contrast, an inhibition of TGF-b with
decorin or octreotide reduces fibrosis in animal models of
PD,8,9 demonstrating the pathogenic role of TGF-b and anti-
TGF-b therapy for peritoneal fibrosis. On the other hand, as
TGF-b is also an anti-inflammatory cytokine and immune
modulator,10 it raises concerns about the long-term con-
sequences of anti-TGF-b treatment. Thus, strategies that aim
at preventing TGF-b-dependent fibrosis need to precisely
target the specific pathway(s) involved in the fibrotic process,
rather than to block the general effects of TGF-b.
It is well established that TGF-b induces expression of
ECM genes through an activation of its downstream signaling
molecules, Smad2/3.11 Upon binding to its receptors, TGF-b
activates receptor-associated Smads (Smad2/3) to mediate
ECM production. Activation of TGF-b signaling also induces
the expression of ‘inhibitory’ Smads, particularly Smad7,
which in turn inhibits Smad2/3 phosphorylation by blocking
their access to TGF-b receptors or by causing the degradation
of TGF-b receptors through a negative-feedback mechan-
ism.12 We and other investigators have recently shown that
specific blockade of the downstream TGF-b pathway by a
gene transfer of Smad7 is able to attenuate TGF-b, high
glucose and advanced glycation end products-induced renal
fibrosis in vitro13–16 and in rat models of obstructive and
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remnant kidney diseases.17–19 Furthermore, overexpression of
Smad7 is also able to inhibit renal inflammation by
inactivation of the nuclear factor-kB signaling pathway.20
We thus hypothesized that blockade of the TGF-b signaling
pathway by a gene transfer of smad7 gene may be able to
attenuate progressive peritoneal fibrosis in a rat model of
chronic PD. Using the ultrasound-microbubble technique,
Smad7 genes were successfully transferred into the peri-
toneum and Smad7 transgene expression was tightly
regulated by doxycycline, which is supplemented in the daily
drinking water. The results demonstrated that overexpression
of Smad7 attenuated peritoneal fibrosis and prevented the
loss of peritoneal function.
RESULTS
Efficacy of ultrasound-microbubble-mediated Smad7 gene
transfection in the peritoneum in normal rats
We first examined the efficacy of ultrasound-microbubble-
mediated, Dox-induced flag-m2-Smad7 transgene expression
within the peritoneum with the anti-flag m2 antibody by
confocal imaging analysis. As shown in Figure 1, after a 3-day
induction of flag-m2-Smad7 expression with Dox in the
drinking water (200 mg/ml), a marked increase of flag m2
expression was detected in the peritoneum in a dose-
dependent manner (Figure 1), accounting for up to 80% of
the peritoneal cells being positive for flag-m2 at a maximal
dose of 100 mg/rat (Figure 1d and e). Indeed, this increase was
confirmed by strong positive staining for flag-m2 in most
peritoneal cells, including mesothelial cells that were lying on
the surface and submesothelial cells (Figure 1d, inserted
picture). In contrast, the peritoneum treated with ultra-
sound-mediated empty vectors (pTRE and Tel-on plasmids)/
Sonovue showed negative staining for the anti-flag m2
antibody (Figure 1a).
We then tested the duration of Smad7 transgene
expression within the peritoneum. As shown in Figure
2a–d, flag-m2-positive cells within the peritoneum peaked at
day 3 after gene transfer, and this peak gradually decreased
afterward, resulting in 70% reduction by day 14. To maintain
the higher levels of Smad7 transgene expression, the second
gene transfer was performed on day 14. Immunohistochem-
ical staining showed that flag-m2 Smad7 expression peaked
again on day 17 (Figure 1e) after the second gene transfer and
reduced subsequently from days 21 to 28 (Figure 1f–h).
Quantitative analysis of flag-m2 Smad7 was shown in Figure
2i. This result was further confirmed by Western blot analysis
with the anti-flag-m2 antibody as shown in Figure 2j.
Overexpression of smad7 attenuates progressive peritoneal
fibrosis and prevents a loss of peritoneal function in a rat
model of PD
Histologically, normal rat peritoneum was thin, consisting of
linear mesothelial cells (Figure 3a) with few ECM deposi-
tions, as indicated by Masson Trichrome staining materials
(Figure 3e). However, a typical feature of peritoneal fibrosis
was developed at 4 weeks after PD, showing a marked
peritoneal thickening with rich ECM accumulation and a loss
of linear mesothelial cells in PD rats that received no
treatment (Figure 3b and f) or those treated with control
plasmids (Figure 3c and g). In contrast, all these changes were
attenuated after treatment with Smad7 (Figure 3d and h).
As shown in Figure 4, compared with normal rats (Figure
4ai and bi), peritoneal function was lost in PD rats (Figure
4aii and bii) and in those treated with control empty
plasmids (Figure 4aiii and biii). This was demonstrated by a
significant reduction of ultrafiltration rate and a rise of mass
transfer of glucose, which was prevented by treatment with
Smad7 (Figure 4iv and biv).
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Figure 1 | Determination of Smad7 gene transfection rate
on the peritoneum by confocal microscope. A Dox-regulated
flag-m2-Smad7 pTRE plasmid (or empty pTRE) and a Tet-on plasmid
(1:1) were mixed with Sonovue in a ratio of 1:1 (vol/vol) and
transfected into peritoneum by an ultrasound-mediated system as
described in Materials and methods. Smad7 transgene expression
was induced by Dox in the drinking water (200 mg/ml) for 3 days,
detected by the anti-flag-m2 antibody and examined by confocal
microscopy as described in Materials and methods. (a) Control
plasmids; (b) Smad7 at a dose of 25mg/rat; (c) Smad7 at a dose of
50mg/rat; (d) Smad7 at a dose of 100 mg/rat; (e) quantitative analysis.
Note that a strong flag-m2-Smad7 expression (green) is detected
within cytoplasm (arrows) in mesothelial cells on the peritoneal
surface (s) and also in cells in submesothelial areas, which is enlarged
at the inserted area of (d). It is shown that Smad7 transgene
expression is, in a dose-dependent manner, peaking at 100 mg/rat,
which results in more than 80% of peritoneal cells being positive for
flag-m2 (d and e). Data represent mean7s.e.m. for groups of four
rats. **Po0.05 compared with a dose of 25 mg/rat; #Po0.05
compared with a dose of 50 mg/rat. Nuclei were counterstained with
DAPI (Red). Original magnification  400.
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Gene transfer of Smad7 prevents upregulation of ECM in
peritoneum after PD
Next, we investigated the potential mechanisms whereby gene
therapy with Smad7 inhibited progressive peritoneal fibrosis
after PD. As shown in Figures 5–7, confocal imaging analysis
showed that compared with normal rats (Figures 5–7a), a
marked increase in the expression of peritoneal a-SMA
(Figure 5), collagen I (Figure 6), and, to a less extent of
collagen IV (Figure 7), matrix accumulation was found in
both PD rats (Figures 5–7b) and those treated with control
plasmids (Figures 5–7c), resulting in the thickening of the
peritoneum. A significant increase in the expression of
a-SMA, collagen I, and collagen IV was further demonstrated
at the mRNA level by reverse transcription-polymerase chain
reaction (RT-PCR) (Figures 5–7e) and at the protein level by
Western blot analysis (Figures 5–7f). In contrast, all these
disease parameters were significantly inhibited in rats treated
with gene transfer of Smad7 (Figures 5–7iv).
Inhibition of TGF-b/Smad signaling is the key mechanism by
which gene transfer of Smad7 prevents peritoneal fibrosis
It is now well established that TGF-b stimulates ECM
production through the Smad signaling pathway.21 We tested
whether inhibition of TGF-b/Smad signaling is a central
mechanism whereby gene transfer of Smad7 prevents
peritoneal fibrosis. As shown in Figure 8, confocal micro-
scopy analysis showed that there were few cells with positive
nuclear staining for Smad2/3 in normal peritoneum (Figure
8a and e), whereas marked activation of Smad2/3 was found
in peritoneum after PD in rats received no treatment (Figure
8b) or were treated with control plasmids (Figure 8c and e).
In contrast, PD rats treated with Smad7 showed a substantial
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Figure 2 | Peritoneal Smad7 transgene expression during the
28-day period determined by confocal microscope and Western
blot analysis. An optimal dose of Smad7 plasmid (100 mg/rat) was
transfected into rat peritoneum as described in Materials and
methods. (a–h) The expression of flag-m2-Smad7 by peritoneal cells
was checked on days 0, 3, 7, 14, 17, 21, 24, and 28. Note that the
expression of flag-m2-Smad7 (green) by peritoneal cells (arrows)
is peaked at day 3 (b, i, and j) and is reduced by 70% at day 14
(d, i, and j). After the second Smad7 gene transfer at day 14,
expression of flag-m2-Smad7 reaches the peak again at day 17
(e, i, and j), but is gradually reduced from day 21 onwards. Data
represent mean7s.e.m. for groups of four rats. *Po0.05, **Po0.01
compared with the control (0). S, peritoneal surface. Nuclei are
counterstained with DAPI (Red). (j) The expression levels of
flag-m2Smad7 transgene in rat peritoneum at various time points
are detected by Western blot analysis. Original magnification  400.
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Figure 3 | Smad7 gene transfer attenuates peritoneal fibrosis in a
rat model of PD at day 28. (a–d) Hematoxylin and eosin staining.
(e–h) Masson Trichrome staining of day-28 parietal peritoneal tissues
after PD. (a) Normal control, (b) PD without treatment, (c) empty
plasmid control, (d) Smad7 treatment. As compared with the normal
(e), a severe peritoneal fibrosis accompanied by the thickening of the
peritoneum with marked deposition of ECM and a loss of mesothelial
cells, is demonstrated in both untreated (f) and empty plasmid
treated (g) animals. However, all these pathological changes are
attenuated after gene therapy with Smad7 (h). Representative images
were taken from groups of 10 rats. Original magnification  400.
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inhibition of Smad2/3 activation (Figure 8d and e). This was
further confirmed by Western blot analysis of phosphorylated
Smad2 and Smad3. As shown in Figure 8f, overexpression of
Smad7 significantly reduced the elevated levels of phos-
phorylated Smad2 and completely blocked the phosphoryla-
tion of Smad3. Interestingly, RT-PCR showed that the levels
of endogenous rat Smad7 remained unchanged (data not
shown).
Gene transfer of Smad7 also inhibited upregulation of
peritoneal TGF-b in both mRNA and protein levels at 4
weeks after PD (Figure 9). Confocal microscopy showed that
only a few cells in normal rat peritoneum were positive for
TGF-b1 (Figure 9a), but numerous peritoneal cells were
strongly positive for TGF-b in PD rats that received no
treatment (Figure 9b) or those treated with control plasmids
(Figure 9c), which were substantially inhibited by gene
transfer of Smad7 (Figure 9d). Similarly, the inhibitory effect
of Smad7 on peritoneal TGF-b expression after PD was
further demonstrated by RT-PCR and Western blotting
(Figure 9e and f). Furthermore, two-color immunofluore-
scent staining with antibodies to ED1 (CD68) and TGF-b1
demonstrated that both peritoneal macrophages (ED1þ )
and mesothelial-like cells (ED1) lining the intact surface of
the peritoneum were highly expressed TGF-b1 (Figure
10a–c). It was further demonstrated in vitro that the addition
of high glucose was able to stimulate rat peritoneal
mesothelial cells to produce TGF-b1 at the mRNA levels
(Figure 10d) and at the secreted protein levels (Figure 10e).
It is known that expression of plasminogen activator
inhibitor-1 (PAI-1) is regulated by TGF-b and is associated
with peritoneal fibrosis.22 Thus, we further examined
whether inhibition of peritoneal fibrosis with gene transfer
of Smad7 is associated with suppression of PAI-1 expression.
There were few cells positive for PAI-1 in normal peritoneum
(Figure 11a and e). In contrast, a large number of PAI-1-
positive cells were apparent in the thickening peritoneum at 4
weeks after PD (Figure 11b, c and e), which was significantly
inhibited by treatment with Smad7 (Figure 11d and e).
Similarly, upregulation of peritoneal PAI-1 mRNA in both
disease and treatment control animals was also significantly
inhibited by gene transfer of Smad7 (Figure 11f).
DISCUSSION
In this study, we demonstrated that TGF-b/Smad signaling
was highly activated in the peritoneum after PD, contributing
to the development of peritoneal fibrosis and resulting in a
loss of peritoneal ultrafiltration. More importantly, we also
demonstrated that blockade of Smad signaling with gene
transfer of inducible Smad7 was able to attenuate fibrosis in
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Figure 4 | Smad7 gene transfer prevents a loss of peritoneal
functions after PD at day 28. (a) Ultrafiltration rate, (b) mass transfer
of glucose (MTG). (i) Normal control, (ii) PD without treatment,
(iii) empty plasmid control, (iv) Smad7 treatment. Data are expressed
as mean7s.e.m. for groups of 10 rats. *Po0.05, **Po0.01 compared
with the normal control (i) #Po0.05 compared with both untreated
PD (ii) and vector control treatment (iii).
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Figure 5 | Smad7 gene transfer inhibits mRNA and protein levels
of peritoneal a-SMA after PD at day 28. (a–d) Confocal microscopy,
(e) RT-PCR amplification, (f) Western blot analysis. (i) Normal control,
(ii) untreated PD, (iii) PD treated empty plasmids, (iv) Smad7
treatment. Note that there are few a-SMA-positive cells (green)
in submesothelial areas of normal peritoneum (a) but numerous
a-SMA-positive cells are found in the mesothelial cell layer, indicating
a myofibroblast transition in the thickened submesothelial areas of
both untreated PD (b), and empty plasmid-treated (c) animals.
However, a-SMA-positive cells within the peritoneum after PD are
significantly inhibited after gene transfer of Smad7 (d). Similar results
are seen at the mRNA (e) and protein (f) levels. S, peritoneal surface.
Data represent mean7s.e.m. for groups of 10 rats. *Po0.05
compared with the normal control (i) #Po0.05 compared with both
untreated PD (ii) and empty plasmid treatment (iii). Nuclei are
counterstained with DAPI (Red). Original magnification  400.
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rat peritoneum with PD, as demonstrated by the reduction of
expression of a-SMA, collagen type I, and collagen type IV.
Moreover, the inhibition of TGF-b/Smad signaling by Smad7
reduced the expression of peritoneal TGF-b and PAI-1. These
findings suggest that ultrasound-microbubble-mediated
Smad7 gene therapy may have therapeutic potential for
prevention and treatment of peritoneal fibrosis induced by
long-term PD.
Increasing evidence shows that peritoneal fibrosis is a
major cause of failure of PD. The understanding of molecular
mechanisms involved in cellular responses leading to
peritoneal fibrosis may ultimately evoke new therapeutic
strategies that protect the peritoneal membrane against
fibrosis of long-term PD. The recent discovery and
characterization of TGF-b/Smad signaling has allowed better
understanding about this process. It is now well accepted that
TGF-b signals through its receptors to activate the down-
stream mediators, including Smad2 and Smad3, to exhibit its
biological effects and this activation is negatively regulated by
Smad7.11,12 In the context of fibrosis, the activation of Smads
has been shown in a number of experimental and human
diseases.15,17–21,23,24 Our recent studies have shown that
blockade of TGF-b/Smad signaling by gene transfer of
Smad7, using the ultrasound-mediated system is able to
inhibit renal fibrosis in rat models of obstructive and
remnant kidney diseases.18,19 The present study also provided
the first evidence that overexpression of Smad7 was able to
block the TGF-b/Smad signaling pathway and prevented
peritoneal fibrosis and a loss of peritoneal functions in a rat
model of PD. Results from this study further demonstrate, at
the molecular signaling level, that TGF-b/Smad signaling
may play a critical role in the development of peritoneal
fibrosis associated with PD. Taken together, all these findings
suggest that overexpression of Smad7 may be a therapeutic
potential for fibrosis in various disease conditions.
Consistent with the previous findings,18,19 inhibition of
Smad2/3 activation was a key mechanism by which over-
expression of Smad7 blocked peritoneal fibrosis. This
inhibition was supported by the following findings: (1) a
significant increase of activation of Smad2/3 in the
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Figure 6 | Smad7 gene transfer inhibits peritoneal collagen I
mRNA and protein expression after PD at day 28. (a–d) Confocal
microscopy, (e) RT-PCR amplification, (f) Western blot analysis.
(i) Normal control, (ii) untreated PD, (iii) PD treated empty plasmids,
(iv) Smad7 treatment. Note that there is a small amount of collagen I
deposition (green) in submesothelial areas of normal peritoneum
(a), but massive collagen I accumulation is found in the thickening
submesothelial areas in both untreated PD (b) and empty plasmid
treated (c) animals. In contrast, collagen I accumulation within the
peritoneum after PD is significantly inhibited after gene transfer of
Smad7 (d). Similar results are observed at the mRNA (e) and protein
(f) levels. S, peritoneal surface. Data represent mean7s.e.m. for
groups of 10 rats. *Po0.05, **Po0.01 compared with the normal
control (i) #Po0.05, ##Po0.01 compared with both untreated PD
(ii) and empty plasmid treatment (iii). Nuclei are counterstained with
DAPI (Red). Original magnification  400.
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Figure 7 | Smad7 gene transfer inhibits peritoneal collagen IV
mRNA and protein expression after PD at day 28. (a–b) Confocal
microscopy, (e) RT-PCR amplification, (f) Western blot analysis.
(i) Normal control, (ii) untreated PD, (iii) PD treated empty plasmids,
(iv) Smad7 treatment. Note that there are a few collagen IV
depositions (green) in the submesothelial areas of normal
peritoneum (a). However, an increased peritoneal collagen IV
accumulation is found in the thickening submesothelial areas in both
untreated PD (b) and empty plasmid treated (c) animals.
Nevertheless, collagen IV accumulation within the peritoneum after
PD is significantly inhibited after gene transfer of Smad7 (d). Similar
results are seen at the mRNA (e) and protein (f) levels. S, peritoneal
surface. Data represent mean7s.e.m. for groups of 10 rats. **Po0.01
compared to the normal control (i) #Po0.05 compared with both
untreated PD (ii) and empty plasmid treatment (iii) Nuclei are
counterstained with DAPI (Red). Original magnification  400.
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peritoneum was associated with severe fibrosis after PD; (2)
an inactivation of Smad2/3 after ectopical induction of
Smad7 resulted in a substantial decrease in fibrotic thicke-
ning of the peritoneum and expression of a-SMA, collagen I,
and collagen IV. In addition, overexpression of peritoneal
Smad7 also prevented a loss of peritoneal functions, such as a
fall of ultrafiltration rate and a rise in glucose transportation.
Thus, activation of TGF-b/Smad signaling plays a critical role
in peritoneal fibrosis after prolonged PD. Our findings that
inflammatory peritoneal macrophages and mesothelial cells
were able to produce TGF-b1 in response to high glucose in
vivo and in vitro are consistent with previous findings that
TGF-b signaling is induced in mesothelial cells by high
concentrations of glucose.4,5 Recently, we also found that
high glucose is able to stimulate renal tubular cells, mesangial
cells, endothelial cells, and vascular smooth muscle cells to
produce ECM through a TGF-b-dependent Smad signaling
mechanism.14 These observations strongly support the
notion that activation of TGF-b/Smad signaling is a key
mechanism in peritoneal fibrosis after long-term exposure to
high concentrations of glucose in the PD fluid.
Inhibition of PAI-1 expression could be another mecha-
nism of Smad7 in the attenuation of peritoneal fibrosis
because PAI-1 is a component of ECM and a target gene of
TGF-b. Several Smad-binding boxes (CAGA) are present in
the PAI-1 promoter.22 Therefore, upregulation of PAI-1 in
peritoneal tissues after PD may be related to the functional
activation of TGF-b/Smad signaling during peritoneal
fibrosis. It has been shown that glucose induces peritoneal
fibrosis by stimulating PAI-1 expression.23 Inhibition of ECM
and PAI-1 on mesothelial cells, in response to glucose and
lipopolysaccharide, can be achieved by blocking TGF-b with
small interfering RNA or antisense strategies.25 Thus,
a b
c d
e f
60 p-Smad2
p-Smad2 p-Smad3
p-Smad3
GAPDH
60 kDa
52 kDa
37 kDa
50 ∗∗
∗∗
∗ ∗∗∗
∗∗∗
∗∗∗
∗
∗,#
40
30
20
10
0.3
0.2
R
at
io
0.2
0.4
0.6
0.1
0.0 0.0
p-
Sm
ad
2+
 
ce
lls
/H
P
0
i iiiiii ii iiiiv iv
i ii iii iv
i ii iii iv
#
###
Figure 8 | Smad7 gene transfer inhibits activation of Smad2/3
in the peritoneum after PD at day 28. (a–d) Confocal microscopy,
(e) semiquantitative analysis, (f) Western blot analysis. (i) Normal
control, (ii) untreated PD, (iii) PD-treated empty plasmids, (iv) Smad7
treatment. Activation of Smad2/3 was detected by both p-Smad2/3
nuclear translocation by confocal microscopy (a–d) and
phosphorylation of p-Smad2 and p-Smad3 by Western blot analysis
(f). Note that few p-Smad2/3 (green) positive cells, as identified by its
nuclear pattern (arrows), are detected in normal peritoneum (a) but
become massive in the thickening peritoneum in both untreated PD
(b) and empty plasmid-treated (c) animals. In contrast, p-Smad2/3-
positive cells (arrows) within the peritoneum after PD are significantly
inhibited after gene transfer of Smad7 (d). Similar results are
observed at the phosphorylated protein levels by Western blotting
analysis with the specific antibody to p-Smad2 or p-Smad3 (f).
S, peritoneal surface. Data represent mean7s.e.m. for groups of 10
rats. *Po0.05, **Po0.01, ***Po0.001 compared with the normal
control (i). #Po0.05, ###Po0.001 compared with both untreated PD
(ii) and empty plasmid treatment (iii). Nuclei are counterstained with
DAPI (Red). Original magnification  400.
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Figure 9 | Smad7 gene transfer inhibits upregulation of
peritoneal TGF-b mRNA and protein after PD at day 28.
(a–d) Confocal microscopy, (e) RT-PCR amplification, (f) Western blot
analysis. (i) Normal control, (ii) untreated PD, (iii) PD treated empty
plasmids, (iv) Smad7 treatment. Although few cells positive for TGF-b
expression (green) are found in normal peritoneum (a), expression of
TGF-b is significantly increased (arrows) in association with the
thickening of the peritoneum in both untreated PD (b) and empty
plasmid treated (c) animals. In contrast, peritoneal TGF-b expression
is significantly inhibited after gene transfer of Smad7 (d), which is
further confirmed at the mRNA and protein levels by RT-PCR (e) and
Western blot analysis (f). S, peritoneal surface. Data represent
mean7s.e.m. for groups of 10 rats. * Po0.05, **Po0.01 compared
with the normal control (i). #Po0.05 compared with both untreated
PD (ii) and empty plasmid treatment (iii). Nuclei are counterstained
with DAPI (Red). Original magnification  400.
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inhibition of PAI-1 expression by overexpression of Smad7
could be one mechanism by which gene therapy with Smad7
attenuates peritoneal fibrosis.
An interesting observation in this study is that blockade of
the Smad activation by Smad7 inhibited peritoneal TGF-b
expression. This may imply that TGF-b production by
peritoneal cells, including inflammatory macrophages and
mesothelial cells during PD, is Smad-dependent and may
suggest that an autoregulatory pathway of TGF-b/Smad
signaling is probably operating in the process of peritoneal
fibrosis during PD. We have recently demonstrated that
overexpression of Smad7 is able to block nuclear factor-kB
activation and nuclear factor-kB-dependent inflammatory
response in vivo and in vitro.20,26 It is also possible that
ectopical induction of Smad7 in the peritoneum is capable
of reducing peritoneal inflammation, thereby suppressing
TGF-b expression.
In summary, we have demonstrated that TGF-b/Smad
signaling may play a critical role in peritoneal fibrosis and
that gene transfer of inducible Smad7 using the ultrasound-
microbubble-mediated system was able to ameliorate peri-
toneal fibrosis in a rat model of PD. The results from this
study suggest that targeting TGF-b/Smad signaling by
ultrasound-mediated gene transfer of Smad7 may provide a
powerful tool for prevention and treatment of peritoneal
complications associated with long-term PD.
MATERIALS AND METHODS
Ultrasound-mediated gene transfer of inducible Smad7
gene-loaded microbubbles into the peritoneum
As described previously,19–20 an ultrasound-microbubble-mediated,
doxycycline-regulated Smad7 expressing plasmid (a gift from
Dr Hong J Zhu) was employed in this study. All plasmids were
prepared using the EndoFree Plasmid kit (Qiagen Inc., Valencia, CA,
USA) according to the manufacturer’s instructions. Briefly, after
mixing pTRE–m2Smad7 and pEFpurop-Tet-on with Sonovue
(Milano company, Bracco s.p.a., Italy) at a ratio of 1:1 (vol/vol),
the mixed solution containing 100 mg of designated plasmids in total
volume of 4 ml was injected into the peritoneal cavity through the
catheter. Immediately after injection, the ultrasound transducer
(FYSIOMED Sonic 15C, Belgium) was directly applied to the surface
of the abdominal skin coated with ultrasound media, and a
disconnected-wave (1/10) at power output of 2.8 W/cm2, 1–3 MHz
was applied. A total of 20-min ultrasound treatment, with the
continuous movement of the probe on the entire abdominal surface
in a 10-min interval at the face-up and -down positions, was used.
This movement allows the ultrasound irradiation to reach the entire
abdominal cavity containing the mixture of Smad7-microbubbles.
The same procedure was applied to the control animals.
Animal model
Male Sprague–Dawley rats at the age of 8 weeks, weighing 180–200 g,
were obtained from Laboratory Animal Center of Sun Yat-Sen
University, Guangzhou, China. A rat model of peritoneal fibrosis
was induced by daily intraperitoneal injection of 4.25% Dianeal
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Figure 10 | Peritoneal cells expressing TGF-b1 demonstrated by two-color immunofluorescent confocal microscopy and mesothelial
cell culture. (a) Macrophages are identified by the mouse monoclonal anti-ED1 antibody followed by Cy3-conjugated goat anti-mouse
antibody (Red). (b) Cells expressing TGF-b1 are detected by a rabbit anti-TGF-b1 antibody followed by fluorescein isothiocyanate-conjugated
goat anti-rabbit antibody (green). (c) Merged images from (a) and (b), showing TGF-b1 expression by ED1þ macrophages (arrows) and
ED1- elongated mesothelial-like cells on the intact peritoneal surface (arrowheads). (d and e) Rat mesothelial cell culture under high
glucose and mannitol that mimic 4.25% Dianeal conditions (214 mM). Results show that high glucose, but not mannitol, is able to stimulate
TGF-b1 mRNA (d) and protein expression (e). *Po0.05, **Po0.01 compared with the normal control (i). #Po0.05 compared with both
untreated PD (ii) and empty plasmid treatment (iii). Nuclei are counterstained with blue. Original magnification  400.
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(Baxter HealthCare, Deerfield, IL, USA) at 100 ml/kg for 4 weeks
and intraperitoneal injection LPS at a dose of 0.6 mg/kg (Sigma,
St Louis, MO, USA) at days 8, 10, 12, 22, 24, and 26.
We first determined an optimal dose of peritoneal Smad7
transfection rate and transgene expression. Groups of four normal
rats received doses of pTRE-m2Smad7 at 25, 50, and 100 mg/ml.
Total volume of 4 ml of the mixture of the contrast agent Sonovue
(Milano company) and pTRE-m2Smad7/Tet-on plasmids at a ratio
of 1:1 (vol/vol) was infused into the peritoneal cavity, followed
immediately by ultrasound treatment for 20 min as described above.
After determining the optimal dose (100 mg/ml), groups of 10 rats
were studied: (i) normal rats received no treatment as an age-
matched normal control; (ii) diseased rats received daily infusion of
4.25% Dianeal without gene transfer; (iii) treatment control rats had
daily infusion of 4.25% Dianeal and received 4 ml of mixed Sonovue
and empty pTRE/Tet-on plasmids (100 mg/ml) at a ratio of 1:1
(vol/vol) and were treated with ultrasound as described above; and
(iv) Smad7-treated rats received daily 4.25% Dianeal infusion and
ultrasound treatment with a mixture of Sonovue and pTRE-
m2Smad7/Tet-on plasmids (100 mg/ml). In order to induce Smad 7,
all rats received a daily dose of doxycycline (Dox, Sigma, St Louis,
MO, USA) at a concentration of 200mg/ml in the daily drinking
water for 4 weeks as described previously.18–20
Peritoneal function test
Before killing the rats, 0.09 ml/g body weight of 4.25% Dianeal was
administered intraperitoneally. Four hours later, the peritoneum was
opened and the fluid was removed for ultrafiltration measurement.
Net ultrafiltration was the volume of fluid removed after 4 h minus
the volume of fluid administered. Peritoneal fluid samples were
centrifuged at 1500 r.p.m. for 5 min. Glucose was measured by a
standard enzymatic test on a Hitachi automated chemistry analyzer
(HITACHI 7170, Japan). Mass transfer of glucose out of the
peritoneum was calculated by using the formula: (initial dialysate
glucose initial volume)(final dialysate glucose final volume).
Histology and confocal imaging analysis
Both parietal and visceral peritoneal tissues were collected at 4 weeks
after PD and fixed in 10% formalin for 24 h. Two-micrometer
paraffin-embedded sections were cut and stained for hematoxylin
and eosin and Masson’s Trichrome. For Confocal Imaging analysis,
6-mm paraffin-embedded sections were cut and stained for
monoclonal or polyclonal antibodies to Flag-M2 (Sigma),
p-Smad2/3 (Santa Cruz Biotechnology, Santa Cruz, CA, USA),
a-SMA (Sigma), collagen I and IV (Santa Cruz), TGF-b1 (Santa
Cruz), and plasminogen activator inhibitor-1 (PAI-1, Santa Cruz) in
41C overnight, followed by a fluorescein isothiocyanate-conjugated
goat anti-mouse or rabbit antibody (Santa Cruz) at 371C for 45 min.
Sections were then counterstained with 40,6 diamidino-2 phenyl-
indole (DAPI) (Molecular Probe, Eugene, OR, USA) and viewed
using a Zeiss LSM 510 Confocal Imaging System (Zeiss, Ober-
kochen, Germany). Specimens were serially excited at 405 nm and
observed at 420–460 nm to detect nuclear DAPI, and then excited at
488 nm and observed at more than 505 nm to detect fluorescein
isothiocyanate. All sections were viewed under identical settings on
the Zeiss Imaging System to ensure accurate interpretation of
relative immunofluorescence. From each section, 5–10 imaging areas
were randomly chosen and analyzed by the Zeiss Image Processing
Software with results reported as the mean intensity of immuno-
fluorescence/mm2, whereas positive cells for Flag-M2 and nucleated
p-Smad2/3 were reported as positive cells/high-power field or
percentage.
To define TGF-b1 expression by peritoneal cells, two-color
immunofluorescent staining was performed. Expression of TGF-b1
was detected with polyclonal rabbit anti-TGF-b1 antibody followed
by fluorescein isothiocyanate-conjugated goat anti-rabbit antibody.
Macrophages were stained with mouse monoclonal anti-ED1
antibody (Chemicon, Temecula, CA, USA) followed by Cy3-
conjugated goat anti-mouse antibody. Images were taken using
Zeiss LSM 510 Confocal Imaging System.
Mesothelial cell culture
Peritoneal mesothelial cells were isolated from male Sprague–Dawley
rats by intraperitoneal injection with a 0.25% trypsin/0.02%
ethylenediaminetetraacetic acid digestion solution for 2 h and
characterized as described previously.6,7,27 The second-generation
cells were then stimulated with high glucose or control mannitol at a
dose equal to 4.25% Dianeal (214 mM) for 0, 3, 6, 12, 24, and 48 h.
TGF-b1 mRNA expression by mesothelial cells, in response to high
glucose or mannitol, was determined by RT-PCR as described below,
whereas total TGF-b1 protein secretion within the cultured media
was measured by an enzyme-linked immunosorbent assay kit
following the manufacturer’s protocol (R&D Systems, Minneapolis,
MN, USA) as described previously.26
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Figure 11 | Smad7 gene transfer inhibits upregulation of PAI-1 in
the peritoneum after PD at day 28. (a–d) Confocal microscopy,
(e) semiquantitative analysis of immunostaining, (f) RT-PCR
amplification. (i) Normal control, (ii) untreated PD, (iii) PD treated with
empty plasmids, (iv) Smad7 treatment. A few cells are positive for
PAI-1 (green) in normal peritoneum (a). However, expression of PAI-1
is largely increased in the thickening peritoneum in both untreated
PD (b) and empty plasmid treated (c) animals, which are significantly
inhibited after gene transfer of Smad7 (d). Data represent
mean7s.e.m. for groups of 10 rats. *Po0.05, **Po0.01 compared
with the normal control (i). #Po0.05 compared with both untreated
PD (ii) and empty plasmid treatment (iii). Nuclei are counterstained
with DAPI (Red). Original magnification  400.
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Western blot analysis
Visceral peritoneum tissues were lysed with cell lysis buffer (Cell
Signaling Technology, Danvers, MA, USA) and proteins were
extracted, denatured at 991C for 5 min, and then transferred to a
nitrocellulose membrane. Nonspecific binding to the membrane was
blocked for 1 h at room temperature with 5% skimmed milk in Tris-
buffered saline buffer (20 mM Tris-HCl, 150 mM NaCl, and 0.1%
Tween 20). The membranes were then incubated overnight at 41C
with primary antibodies against Flag-m2, p-Smad2, and p-Smad3
(Cell Signaling), a-SMA, collagen I and IV, TGF-b1, and
glyceraldehyde-3-phosphate dehydrogenase. After being washed
extensively, the membrane was incubated with a 1:1000 dilution
of peroxidase-conjugated goat anti-mouse IgG or goat anti-rabbit
IgG (Santa Cruz) in Tris-buffered saline containing 5% skimmed
milk powder for 1 h. The signals were visualized by an enhanced
chemiluminescence system (GE, Piscataway, NJ, USA) and were
subjected to glyceraldehyde-3-phosphate dehydrogenase.
RNA isolation and RT-PCR
Total peritoneal RNA was isolated from visceral peritoneum using
Trizol Reagent (Invitrogen Life Technologies, Carlsbad, CA, USA)
according to the manufacturer’s instruction. Complementary DNA
was synthesized from 2 mg total RNA using the ThermoScriptTM
RT-PCR kit (Invitrogen). Afterward, RT-PCR products were
resolved on 1.2–2.0% agarose gels in 1 Tris-borate-ethylenedi-
aminetetraacetic acid buffer, visualized by ethidium bromide, and
photographed using a gel 1000 ultraviolet documentation system
(Bio-Rad, Hercules, CA, USA). All samples were subjected to
RT-PCR for housekeeping gene glyceraldehyde-3-phosphate
dehydrogenase for densitometry. The PCR primers used were:
Glyceraldehyde-3-phosphate dehydrogenase:
forward 50-GGCAAGTTCAATGGCACAGT-30, reverse 50-AAGGTG
GAGGAATGGGAGTT-30;
TGF-b1: forward 50-CTGTCCAAACTAAGGCTCGC-30,
reverse 50-AGACAGCCACTCAGGCGTA-30;
a-SMA: forward 50-GCTCTGTAAGGCGGGCTTTG-30,
reverse 50-ACGAAGGAATAGCCACGCTCA-30;
Collagen I: forward 50-GGTAACGATGGTGCTGTCGG-30,
reverse 50-GGGACCTTGAACTCCAGCAG-30,
Collagen IV: forward 50-ACAGGGATTTGCGTAACTA-30,
reverse 50-TGGTGTTTTCACATTCGGT-30,
PAI-1: forward 50-TACGACATCCTGGAACTGCC-30,
reverse 50-GGAGGAAGACGCCACTGT-30,
Statistical analyses
Data obtained from this study were expressed as the mean7s.d.
Statistical analyses were performed by using SPSS11.0, and
differences within the groups were assessed by one-way ANOVA,
followed by Student’s t-test.
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